MedTrace Logo

Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)

NCT01034969 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1761

Last updated 2024-10-28

No results posted yet for this study

Summary

The Icatibant Outcome Survey (IOS) is a prospective, observational disease registry designed to document the routine clinical outcomes over time in participants with angioedema treated with Firazyr® (icatibant) and/or Cinryze® (C1 inhibitor \[human\]) in countries where it is currently approved. The data collected will be used to evaluate the safety of Firazyr (icatibant) and Cinryze (C1 inhibitor \[human\]) in routine clinical practice and as a data source for post-marketing investigations.

Conditions

  • Hereditary Angioedema (HAE)

Sponsors & Collaborators

  • Takeda Development Center Americas, Inc.

    collaborator INDUSTRY

  • Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda Development Center Americas

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-10
Primary Completion
2024-05-31
Completion
2024-05-31

Countries

  • Australia
  • Austria
  • Brazil
  • Czechia
  • Denmark
  • France
  • Germany
  • Greece
  • Ireland
  • Israel
  • Italy
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01034969 on ClinicalTrials.gov